From a clinical perspective, B7-H3 targeting may represent a promising therapeutic option for HRD-negative ovarian cancer patients, who currently have limited treatment alternatives, and may further enhance efficacy by addressing B7-H3-expressing components of the tumor microenvironment, such as tumor vasculature and cancer-associated fibroblasts. This evidence concerns the gene CD276 and cancer.